Alzheimer Europe's July-August 2025 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.

Summaries of a few of our top stories appear below.

Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.

We are always happy to receive feedback, or suggestions regarding news items to share.

On 25 July, following a re-examination of its initial, negative opinion, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on Lilly’s marketing authorisation application for donanemab for the treatment of early Alzheimer’s disease. Alzheimer Europe welcomes the positive opinion by the CHMP.

In July, Sarah Campill (Public Involvement Officer, Alzheimer Europe) travelled with Jan Runar Eliassen (member of the European Working Group of People with Dementia, from Norway) and his wife Marion Tur Eliassen to Toronto (Canada) to speak at and participate in the Alzheimer’s Association International Conference 2025 (AAIC25). Jean Georges (Executive Director, Alzheimer Europe) also attended the conference. 

Our Annual Conference #35AEC is taking place in just over a month, in Bologna (6 to 8 October). We can’t wait to see everyone, there. If you haven’t yet registered, please make sure you do so before 21 September, to benefit from the current registration rate, which will increase after that deadline. The detailed programme is on our website - check it out!